A landmark Japanese RCT showed enteric-coated bovine lactoferrin at 300 mg/day reduced visceral fat by 15-19 cm² over 8 weeks in adults with abdominal obesity, with no dietary or exercise change. Here's what the trial found, what subsequent research adds, and how to use it.
Most "fat loss" supplements are evidence-poor and effect-poor. Bovine lactoferrin is one of the few exceptions: a Japanese RCT published in the British Journal of Nutrition (Ono et al., 2010) randomized 26 adults with abdominal obesity to either enteric-coated bovine lactoferrin 300 mg/day or placebo for 8 weeks. The lactoferrin group lost a mean of 15.4 cm² of visceral fat (measured by CT), 7.0 cm² of subcutaneous fat, and 1.7 cm of waist circumference — without any change in diet or exercise. The placebo group showed essentially no change.
The effect size is modest in absolute terms but unusual in mechanism: lactoferrin appears to directly affect adipocyte biology through pathways distinct from appetite suppression or thermogenesis. This article walks through what's actually known and how to apply it.
Ono et al. (2010) is the foundational study:
The effect on visceral fat (the metabolically active intra-abdominal fat that drives cardiometabolic risk) was particularly striking — roughly 8% reduction in 8 weeks without lifestyle change.
The trial specifically used enteric-coated lactoferrin. The researchers and subsequent mechanistic work suggest the bioactivity for fat reduction depends on intact lactoferrin reaching the small intestine. Standard non-coated capsules are largely digested by gastric pepsin and acid; enteric-coated formulations deliver intact protein to the duodenum and beyond, where the relevant adipocyte signaling pathways are activated.